Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

BALVERSA 3 MG

ERDAFITINIB : 3 MG · DIN 02493217 · JANSSEN INC

Health Canada status: MARKETED

BALVERSA 3 MG TABLET - DIN 02493217
BALVERSA — DIN 02493217. Product photograph held by Nexara Health.

What is BALVERSA?

BALVERSA 3 MG contains ERDAFITINIB : 3 MG. It is listed in the Health Canada Drug Product Database under DIN 02493217, held by JANSSEN INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 09-Dec-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

Product details and regulatory record

DIN02493217
Brand nameBALVERSA
Generic / active ingredientERDAFITINIB : 3 MG
ManufacturerJANSSEN INC
Strength3 MG
Dosage formTABLET
Route of administrationORAL
SchedulePrescription
ATC codeL01EN01 ERDAFITINIB
AHFS class10:00.00
BiosimilarNo
Health Canada statusMARKETED
Status date09-Dec-2019
Original market date2019-12-09 00:00:00

What can be used instead?

Other Canadian products sharing ATC code L01EN01 ERDAFITINIB. 3 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
BALVERSA4 MGTABLETJANSSEN INCMARKETEDDIN 02493225
BALVERSA5 MGTABLETJANSSEN INCMARKETEDDIN 02493233
BALVERSA4 MGTABLETJANSSEN INCAPPROVEDDIN 02493241

Who else supplies ERDAFITINIB worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. ERDAFITINIB appears in 26 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for BALVERSA

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for BALVERSA

Health Canada Drug Product Database (DPD), DIN 02493217. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.